论文部分内容阅读
将小鼠分成5组:正常组(阴性对照组)、89Sr组(阳性对照组)、89Sr+烟酰胺(Nicotinamide)组(89Sr+N)、89Sr+Carbogen组(89Sr+C)和Sr+Nicotinamide+Carbogen组(89Sr+N+C)。按分组注射烟酰胺和/或吸89入气体Carbogen,两对照组注射相同体积生理盐水SrCl。采用尾静脉“弹丸”注射,体积为200μL含有放射89性活度为7400kBq。阴性对照组注射相同体积生理盐水。于注射后第1、2、3、4、6、8、15、20、30、60、90天批量处死小鼠进行骨髓嗜多染红细胞微核测定。结果显示:各治疗组微核频率随观察时间呈双峰,各组双峰出现时间范围第1峰在第2—4天,第2峰在第10—14天。阴性对照和阳性对照组微核产生频率比较有显著性差异,P<0.01(F=15.517)。其余各组(89Sr+N+C、89Sr、89Sr+N和Sr+C)间相比较无显著性差异,89P>0.05。不同品系(昆明系小鼠、NIH小鼠、BALB/c和F1小鼠)小鼠各组间微核产生频率强度无差异,P>0.05。表明增敏各组与89Sr组之间微核产生平均频率没有统计学差异,提示增敏剂的应用未增加骨髓毒性。
The mice were divided into 5 groups: normal group (negative control group), 89Sr group (positive control group), 89Sr + Nicotinamide group (89Sr + N), 89Sr + Carbogen group (89Sr + C) and Sr + Nicotinamide + Carbogen Group (89Sr + N + C). Nicotinamide was injected in groups and / or Carbogen was inhaled, and the two control groups were injected with the same volume of saline SrCl. The tail vein injection of “projectile”, a volume of 200μL contains radioactivity 89 activity 7400kBq. The negative control group was injected with the same volume of normal saline. Mice were sacrificed in batches on days 1, 2, 3, 4, 6, 8, 15, 20, 30, 60 and 90 days after injection for micronucleus test of bone marrow polychromatic erythrocytes. The results showed that: the frequency of micronuclei in each treatment group showed a double peak with the observation time, the first peak of each peak appeared in the first 2-4 days, the second peak in the first 10-14 days. There was a significant difference in the frequency of micronuclei between negative control group and positive control group, P <0.01 (F = 15.517). There was no significant difference between the other groups (89Sr + N + C, 89Sr, 89Sr + N and Sr + C), 89P> 0.05. There was no difference in the frequency of micronuclei in different groups (Kunming mice, NIH mice, BALB / c mice and F1 mice), P> 0.05. The results showed that there was no significant difference in the average frequency of micronuclei produced between the sensitized groups and the 89Sr group, suggesting that the application of sensitizers did not increase the myelotoxicity.